NASDAQ:PCRX

Pacira BioSciences Stock Forecast, Price & News

$63.07
-3.27 (-4.93 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$60.72
Now: $63.07
$64.88
50-Day Range
$66.34
MA: $70.38
$74.45
52-Week Range
$33.47
Now: $63.07
$80.00
Volume1.01 million shs
Average Volume488,850 shs
Market Capitalization$2.77 billion
P/E Ratio22.21
Dividend YieldN/A
Beta1.27
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.
Pacira BioSciences logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560
Employees624
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$421.03 million
Cash Flow$1.48 per share
Book Value$8.51 per share

Profitability

Net Income$-11,020,000.00

Miscellaneous

Market Cap$2.77 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up to $67.49
April 7, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

2.12 out of 5 stars

Medical Sector

34th out of 2,024 stocks

Pharmaceutical Preparations Industry

14th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 4.4 5 -4 -3 -2 -1 -
$63.07
-3.27 (-4.93 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pacira BioSciences (NASDAQ:PCRX) Frequently Asked Questions

Is Pacira BioSciences a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pacira BioSciences stock.
View analyst ratings for Pacira BioSciences
or view top-rated stocks.

What stocks does MarketBeat like better than Pacira BioSciences?

Wall Street analysts have given Pacira BioSciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pacira BioSciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Pacira BioSciences' next earnings date?

Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Pacira BioSciences
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its quarterly earnings results on Wednesday, February, 24th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.81 by $0.06. The company earned $130.90 million during the quarter, compared to analyst estimates of $130.91 million. Pacira BioSciences had a net margin of 29.95% and a trailing twelve-month return on equity of 10.71%. The firm's revenue for the quarter was up 6.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.56 EPS.
View Pacira BioSciences' earnings history
.

How has Pacira BioSciences' stock price been impacted by Coronavirus (COVID-19)?

Pacira BioSciences' stock was trading at $35.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PCRX stock has increased by 79.2% and is now trading at $63.07.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PCRX?

12 brokerages have issued twelve-month price objectives for Pacira BioSciences' stock. Their forecasts range from $48.00 to $94.00. On average, they anticipate Pacira BioSciences' share price to reach $77.50 in the next year. This suggests a possible upside of 22.9% from the stock's current price.
View analysts' price targets for Pacira BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Pacira BioSciences' key executives?

Pacira BioSciences' management team includes the following people:
  • Mr. David M. Stack, Chairman & CEO (Age 71, Pay $1.47M)
  • Mr. Charles A. Reinhart III, CPA, M.B.A., Chief Financial Officer (Age 60, Pay $637.22k)
  • Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 47, Pay $727.97k)
  • Dr. Roy Winston, Chief Clinical Officer (Age 60, Pay $647.06k)
  • Mr. Max Reinhardt, Pres of ROW (Age 50, Pay $619.19k)
  • Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 42)
  • Mr. Charles Laranjeira, Chief Technical Officer (Age 55)
  • Susan Mesco, Head of Investor Relations
  • Mr. Richard Kahr, VP of HR
  • Mr. Robert J. Weiland, Sr. VP of Alliance Management (Age 61)

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences CEO Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among Pacira BioSciences' employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Pacira BioSciences' key competitors?

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.26%), Hodges Capital Management Inc. (0.17%), State of Alaska Department of Revenue (0.07%), HGK Asset Management Inc. (0.03%), First Hawaiian Bank (0.02%) and Crossmark Global Holdings Inc. (0.02%). Company insiders that own Pacira BioSciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings, Richard Scranton and Roy Winston.
View institutional ownership trends for Pacira BioSciences
.

Which institutional investors are selling Pacira BioSciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Veriti Management LLC, and NEXT Financial Group Inc. Company insiders that have sold Pacira BioSciences company stock in the last year include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences
or view top insider-selling stocks.

Which institutional investors are buying Pacira BioSciences stock?

PCRX stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., Hodges Capital Management Inc., Everence Capital Management Inc., Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Rothschild Investment Corp IL, HGK Asset Management Inc., Crossmark Global Holdings Inc., and First Hawaiian Bank.
View insider buying and selling activity for Pacira BioSciences
or or view top insider-buying stocks.

How do I buy shares of Pacira BioSciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $63.07.

How much money does Pacira BioSciences make?

Pacira BioSciences has a market capitalization of $2.77 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis.

How many employees does Pacira BioSciences have?

Pacira BioSciences employs 624 workers across the globe.

What is Pacira BioSciences' official website?

The official website for Pacira BioSciences is www.pacira.com.

Where are Pacira BioSciences' headquarters?

Pacira BioSciences is headquartered at 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.